Please assess the completion status of the following clinical trial:

Trial Title: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of congenital C1-INH deficiency (HAE type I or II) and assessed by the investigator to likely require intravenous (IV) Berinert treatment during the study period.~* Male or female, ≥ 12 years of age at the time of signing informed consent.~* Written informed consent for study participation obtained before undergoing any study specific procedures.~Exclusion Criteria:~* Incurable malignancies in the last 6 months prior to study entry.~* Acquired angioedema due to C1-INH deficiency.~* All other types of angioedema not associated with C1-INH deficiency.~* Use of any C1-INH products other than Berinert within 30 days before the study, or planned use during the study.~* Immunization within 30 days prior to study entry.~* Autoimmune conditions requiring use of immunosuppressants during the study.~* Known or suspected hypersensitivity to C1-INH.~* Participation in any of the previous Berinert studies from which anti-C1-INH antibody results were submitted to the Food and Drug Administration.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Berinert (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).